What Counts as Evidence

This is the third post of three in a series leading up to the 16th annual International Forum on Consciousness, taking place in Madison this May. Hosted by the BTC Institute, Promega and Usona Institute, the forum gathers scientists, philosophers, and practitioners from dozens of different fields to investigate the nature of the mind. This year’s theme, “Unspoken Intelligence,” explores forms of perception and knowing that fall outside conventional cognition.

In 1845, mathematician Urbain Le Verrier calculated where an unseen planet had to be based on irregularities in Uranus’s orbit, wrote a letter to an observatory telling them where to point their telescope, and Neptune was there. He found a planet without ever looking up.

This is what third-person inquiry looks like at its best: observe from the outside, measure what anyone with the right instruments can measure, build a model precise enough to predict what no one has seen yet. Then look. The history of science is full of such moments, equations pointing to phenomena that hadn’t been detected, particles that hadn’t been observed, forces that hadn’t been measured. The method works because it is ruthlessly disciplined about what counts as evidence. The observer is removed, the conditions controlled, and the measurement trusted.

That discipline is not a limitation. It is the engine of over four centuries of extraordinary results. It gave us germ theory, the structure of DNA, and the sequenced human genome. Every time something seemed to resist physical explanation, the method eventually found the mechanism and the method held. The winning streak was long enough that the assumption underneath it stopped looking like an assumption. Outside-in, third-person, measurable evidence stopped looking like one way of knowing. It started looking like the definition of knowing itself.

The assumption felt safe because it had earned its confidence. Digestion, heredity, mental illness, each had seemed to resist physical explanation until it didn’t. The pattern was consistent enough that the method felt inevitable rather than chosen.

Then science turned toward consciousness, and the winning streak entered dangerous territory.


Here is the problem, what philosopher David Chalmers named the “hard problem” of consciousness in 1995.

To understand what Chalmers meant, it helps to start with his own illustration. When you see red, something measurable happens. Light hits the retina. Signals travel along the optic nerve. Specific regions of the visual cortex activate in patterns that neuroscientists can map with increasing precision. All of that is, in principle, fully describable by the third-person, outside-in approach. Given enough time and instruments, you can trace the whole sequence.

What you cannot describe from the outside is what red looks like. The redness of red, that specific quality of experience that exists only in the moment of seeing it, is not in the neural map. No better scanner will find it there, because the felt quality of the experience isn’t a physical thing hiding in the data. It exists only from the inside. The outside measurement, however precise, cannot reach it.

Chalmers used “hard” deliberately, in contrast to what he called the “easy problems” of consciousness: how the brain integrates information, focuses attention, produces behavior. Those are genuinely difficult, but the outside-in approach knows how to go after them. The hard problem is different in kind. It’s the question that remains even after you’ve solved all of the “easy” ones: why does any of it feel like anything at all?

Think of it this way: everything the brain does could, in principle, happen without any felt experience attached. Processing, responding, behaving, all of it could run like a machine in the dark, with no one home. The question Chalmers is asking is why it doesn’t. Philosophers ask it this way: why is there something it’s like to be you, right now, reading this?

No amount of outside-in evidence, however precise, touches that question, not because the science is insufficient but because the method was specifically designed to exclude first-person data. That exclusion was the whole point. It’s what made the outside-in approach so powerful everywhere else.

With consciousness, the method’s central design decision runs into a question it wasn’t built to answer: how do you study first-person experience when your method was built to exclude first-person data?

Continue reading “What Counts as Evidence”

The Filter You Didn’t Choose

This is the second post in a series leading up to the 16th annual International Forum on Consciousness, taking place in Madison this May, hosted by the BTC Institute, Promega and Usona Institute. The Forum gathers scientists, philosophers, and practitioners from dozens of different fields to investigate the nature of the mind. This year’s theme, “Unspoken Intelligence,” explores forms of perception and knowing that fall outside conventional cognition.

When she thought about a dog, she saw a dog, more specifically, every dog she had ever encountered, cycling through her mind like a card catalog with pictures attached. She assumed everyone did this. When she discovered they didn’t, that most people access something more like an abstract concept hovering somewhere between language and image, she was genuinely surprised. Temple Grandin had always known her mind didn’t work the way people expected. What she didn’t know, until she was an adult, was the specific shape of the difference.

Most of us know this story, or one like it. We understand that some minds filter experience differently, but the science on this doesn’t stop where the conversation usually does.


For most of its history, the field that mapped minds like Grandin’s looked at those that didn’t fit the available systems and concluded the minds were broken. (It didn’t ask whether the systems were.) More recently, the conversation has been reframing those minds not as deficient but as different.

For many people, that reframing has been transformative, changing how educators teach, how clinicians diagnose, and how workplaces are designed. We are now more familiar with alternative cognitive profiles such as autistic pattern recognition (like that experienced by Grandin), ADHD-associated divergent thinking, and the hyper-focused depth of what researchers call monotropic attention. These are not broken versions of normal cognition. They are different architectures, each with genuine capabilities that other minds aren’t built to produce.

The terms most commonly used to describe these differences, neurotypical and neurdivergent, are useful shorthand but they describe a binary the underlying biology doesn’t support. Cognitive traits distribute across a population the way most biological traits do. “Neurotypical” minds are simply closer to the statistical center. What we call “neurodivergent” can be better understood as the part of that population that differs visibly enough from the statistical center to make the variation impossible to ignore.


Continue reading “The Filter You Didn’t Choose”

Light Has a Favorite Color, But It’s Complicated

Last spring, my niece and I made a trip to a home improvement store to put together a Mother’s Day planter for my sister. My niece had a clear vision: my sister’s favorite color is blue, so we were going to buy blue flowers. We walked every aisle of the garden center. We checked the annuals, the perennials, and the hanging baskets then left with purple, red, and a grumpy 7-year-old.

It turns out we were not up against a bad selection. We were up against biology.

The Problem with Blue

Blue is one of the rarest colors in the natural world. The food industry is currently finding that out the hard way. There is a good chance you have eaten something blue today. Maybe it was the frosting on a birthday cake, the coating on some M&M’s® candies, or the sports drink in your refrigerator. That blue almost certainly came from a petroleum-based synthetic dye, and for the first time in decades, the food industry is being asked to find something better.

The FDA banned Red Dye No. 3 in January 2025, and pressure has been building around the remaining synthetic dyes ever since, including Blue No. 1 and Blue No. 2. Major food brands have begun announcing plans to reformulate.

There is just one problem. Blue is genuinely, stubbornly hard to make in nature. It turns out that blue has almost nothing to do with color, and almost everything to do with light.

Continue reading “Light Has a Favorite Color, But It’s Complicated”

Trends and Tools Transforming Drug Discovery: Five Takeaways from Discover Glo 2025

In biologics, cell therapy, and targeted protein degradation, the science is moving fast—and so are the tools. From GPCR-targeted therapies to real-time CAR-T manufacturing tools, new techniques are reshaping how scientists approach drug development, live-cell imaging, and protein degradation.

The “Bringing Light to Science” Discover Glo 2025 speaker series brought together researchers from across academia and industry to share real-world examples of how bioluminescent technologies are helping them advance their research. Now available on demand, these sessions offer fresh perspectives and actionable takeaways on the future of therapeutic development, cellular analysis and assay design.

We’ve distilled five key takeaways from the sessions—practical insights you can apply to your own work or use to stay current with where the field is heading.

Continue reading “Trends and Tools Transforming Drug Discovery: Five Takeaways from Discover Glo 2025”

Non-Pharmacological Approaches to ADHD: Exploring Inflammation and Omega-3s

Attention-Deficit/Hyperactivity Disorder (ADHD) is a complex neurodevelopmental disorder that affects millions worldwide. Current therapeutic treatment relies on pharmaceutical approaches, but emerging research suggests that dietary supplements, such as omega-3 fatty acids, may offer complementary therapeutic options. A recent study published in the Journal of Psychiatric Research explores the relationship between inflammation and dietary supplements to determine how they might influence ADHD pathology. This work was conducted in Dr. Edna Grünblatt’s lab at the University of Zurich and was supported through Promega’s Academic Access Program. I had the chance to interview Dr. Natalie Walter, the lead author, to learn more about how her work offers potential opportunities for non-pharmacological interventions.

Continue reading “Non-Pharmacological Approaches to ADHD: Exploring Inflammation and Omega-3s”

Beyond Ozempic: The New Frontier of Obesity Research

Today’s blog is written by guest blogger, Alden Little, Marketing Intern at Promega.

From genetics to gut microbes, scientists are finding new ways to make white fat act like calorie-burning brown fat. Here’s how three research teams are working to find the next breakthrough obesity treatment.

Rethinking Fat: How New Research is Transforming Obesity Science

Obesity affects millions worldwide and remains a complex challenge shaped by diet, environment, genetics, and socio-economic factors. While medications like semaglutide have shown promise in supporting weight loss, there’s growing interest in alternative strategies.

One area gaining traction is adipose tissue biology. Adipose tissue—commonly known as body fat— is not just a passive storage site for excess energy, but an active player in regulating metabolism and energy balance. Adipose tissue comes in several forms:

  • White
  • Brown
  • Beige

Most of the fat in our bodies is called white adipose tissue (WAT). It stores energy for later use—but too much of it increases the risk for obesity, diabetes, and other health problems. In contrast, brown adipose tissue (BAT) burns energy to generate heat through a process called thermogenesis, helping regulate body weight and temperature. Scientists have discovered a third kind, called beige adipose tissue, which behaves like BAT but can form within WAT under certain conditions like cold exposure or specific molecular triggers.

Continue reading “Beyond Ozempic: The New Frontier of Obesity Research”

Alzheimer Disease and Metabolic Dysfunction: A Critical Intersection in Brain Health

This guest blog post is written by Alden Little, a Marketing Intern at Promega.

Alzheimer disease (AD) is one of the most devastating neurodegenerative disorders, affecting millions worldwide. While much attention has been given to amyloid plaques and tau tangles, emerging research suggests that metabolic dysfunction in the brain plays a crucial role in the disease’s progression. A recent study published in Acta Neuropathologica by Schröder et al. sheds new light on how astrocytes—the brain’s metabolic support cells—are affected in AD, and how their dysfunction impacts neurons.

Auguste Deter, a patient of Dr. Alzheimer, who first described the hallmark plaques and tangles of AD.
Continue reading “Alzheimer Disease and Metabolic Dysfunction: A Critical Intersection in Brain Health”

Ice Age Secrets: The Discovery of a Juvenile Sabretooth Cat Mummy 

In the permafrost of Siberia, a remarkable discovery has been made—a mummified juvenile sabretooth cat, Homotherium latidens, frozen in time for over 35,000 years. This discovery, made along the Badyarikha River in the Indigirka River Basin of Yakutia, Russia, offers an exciting glimpse into a species that has no modern analog (a living equivalent of something extinct) (1). For paleontologists and evolutionary biologists, it provides an unprecedented look at an ancient predator that roamed the Earth during the Ice Age. So, how is this cub mummy truly fascinating scientists?  

A Rare Find  

Homotherium Sabretooth mummy
The frozen mummy of Homotherium latidens: (A) external appearance; (B) skeleton, CT-scan, dorsal view (1).

The permafrost of Siberia is a treasure trove of Ice Age fossils, but the discovery of a mummified Homotherium cub stands out for its rarity and significance. While bones can tell us a lot about the history of an extinct species, mummies—where the animal’s soft tissues, such as fur, skin and sometimes internal organs, are preserved—offer far more detailed information. ‘Mummies’ refer to animals (or humans) that have been preserved with their soft tissues intact, often through natural or intentional processes like drying or embalming. This preservation allows scientists to gain insights into the organism’s diet, health, development and adaptations—details that bones alone can’t reveal! 

Continue reading “Ice Age Secrets: The Discovery of a Juvenile Sabretooth Cat Mummy “

Thanksgiving Cooking: Lessons in Chemistry

Thanksgiving dinner

With Thanksgiving just around the corner, kitchens across the country will soon be alive with the sights, smells and sounds of cooking. But what if we dove deeper into those recipe books and looked beyond the instructions? You might find you’re more than just a cook; you’re quite the chemist!  

Inspired by the popular show Lessons in Chemistry, an adaptation of Bonnie Garmus’s bestselling novel, cooking is presented as applied science, encouraging viewers to think critically about their cooking and the chemical reactions that create the flavors and textures they love. In this blog, we’ll explore the chemistry behind Thanksgiving cooking, revealing how different techniques bring out the best in each dish. 

Continue reading “Thanksgiving Cooking: Lessons in Chemistry”

Third Annual Targeted Protein Degradation Symposium: Embracing the Excitement of Discovery

The third annual Targeted Protein Degradation (TPD) Symposium just wrapped up last month. It was kicked off with Poncho Meisenheimer, VP of Research and Development at Promega, likening the gathering of researchers to “kids in a biology candy store.” This playful analogy captured the vibrant energy and sense of exploration among the attendees, who convened to delve into the future possibilities of proximity-induced degradation. Poncho left attendees with three key questions to consider throughout the symposium:

  1. How can we focus on quantitative measures of cellular events in relevant models?
  2. How do we generate results that serve both human and AI models?
  3. How do we best embrace the excitement of discovery?

Nearly 150 participants from both industry and academia attended the two-day symposium. It was held on September 11th and 12th at Promega’s R&D hub, the Kornberg Center, in Madison, Wisconsin. The event, now in its third year, provided a familiar environment where collaborations flourished, and many attendees rekindled connections forged through previous interactions or partnerships in the field.

Continue reading “Third Annual Targeted Protein Degradation Symposium: Embracing the Excitement of Discovery”